Cellectar Cash vs Current Deferred Revenue Analysis

CLRB Stock

USD 1.58 0.02 1.28%

Cellectar Biosciences financial indicator trend analysis is way more than just evaluating Cellectar Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cellectar Biosciences is a good investment. Please check the relationship between Cellectar Biosciences Cash and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

Cash vs Current Deferred Revenue

Cash vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cellectar Biosciences Cash account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Cellectar Biosciences' Cash and Current Deferred Revenue is 0.47. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Cellectar Biosciences, assuming nothing else is changed. The correlation between historical values of Cellectar Biosciences' Cash and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Cellectar Biosciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Cash i.e., Cellectar Biosciences' Cash and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cash

Cash refers to the most liquid asset of Cellectar Biosciences, which is listed under current asset account on Cellectar Biosciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Cellectar Biosciences customers. The amounts must be unrestricted with restricted cash listed in a different Cellectar Biosciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Cellectar Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cellectar Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.At present, Cellectar Biosciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 70.48, whereas Tax Provision is forecasted to decline to (56.7 K).

	2021	2022	2023	2024 (projected)
Net Interest Income	2.3K	152.5K	395.4K	415.1K
Interest Income	2.3K	152.5K	395.4K	649.7K

Net Interest Income Interest Income

Cellectar Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Non Current Liabilities Total	Current Deferred Revenue	Short Term Debt	Short Long Term Debt Total	Other Liab	Other Assets
Total Assets		-0.02	0.04	0.95	-0.33	-0.99	-0.38	0.11	0.99	-0.4	-0.09	0.99	0.31	0.17	0.82	0.5	0.03	-0.39	0.99	0.38	-0.26	0.44	-0.2	-0.23	0.41	0.51
Other Current Liab	-0.02		0.93	-0.31	0.13	0.05	-0.64	0.65	-0.01	-0.05	-0.31	-0.01	0.33	0.75	0.04	0.57	0.93	0.44	-0.01	-0.02	-0.21	0.56	-0.21	-0.14	0.35	-0.03
Total Current Liabilities	0.04	0.93		-0.29	-0.02	-0.01	-0.83	0.87	0.05	-0.2	-0.28	0.05	0.32	0.91	0.18	0.76	1.0	0.36	0.06	-0.11	-0.25	0.67	-0.25	-0.17	0.52	0.06
Total Stockholder Equity	0.95	-0.31	-0.29		-0.32	-0.95	-0.1	-0.19	0.93	-0.33	-0.01	0.93	0.19	-0.14	0.73	0.23	-0.3	-0.5	0.93	0.39	-0.17	0.2	-0.11	-0.17	0.24	0.47
Property Plant And Equipment Net	-0.33	0.13	-0.02	-0.32		0.42	0.31	-0.17	-0.42	0.9	0.3	-0.42	0.21	-0.14	-0.6	-0.35	0.01	0.9	-0.42	0.2	-0.34	-0.19	-0.42	-0.31	-0.38	-0.43
Net Debt	-0.99	0.05	-0.01	-0.95	0.42		0.38	-0.08	-1.0	0.49	0.15	-1.0	-0.27	-0.15	-0.85	-0.5	0.0	0.48	-1.0	-0.34	0.2	-0.44	0.13	0.17	-0.43	-0.52
Retained Earnings	-0.38	-0.64	-0.83	-0.1	0.31	0.38		-0.87	-0.41	0.49	0.25	-0.41	-0.31	-0.91	-0.54	-0.99	-0.82	-0.01	-0.42	0.11	0.37	-0.81	0.35	0.3	-0.8	-0.22
Accounts Payable	0.11	0.65	0.87	-0.19	-0.17	-0.08	-0.87		0.13	-0.29	-0.16	0.13	0.34	0.94	0.33	0.82	0.87	0.23	0.14	-0.12	-0.19	0.62	-0.21	-0.14	0.56	0.23
Cash	0.99	-0.01	0.05	0.93	-0.42	-1.0	-0.41	0.13		-0.49	-0.15	1.0	0.29	0.19	0.85	0.53	0.05	-0.45	1.0	0.34	-0.21	0.47	-0.14	-0.18	0.44	0.51
Non Current Assets Total	-0.4	-0.05	-0.2	-0.33	0.9	0.49	0.49	-0.29	-0.49		0.51	-0.49	0.08	-0.33	-0.64	-0.52	-0.17	0.77	-0.5	0.17	-0.31	-0.47	-0.38	-0.31	-0.49	-0.3
Non Currrent Assets Other	-0.09	-0.31	-0.28	-0.01	0.3	0.15	0.25	-0.16	-0.15	0.51		-0.15	0.17	-0.2	-0.23	-0.24	-0.26	0.21	-0.15	0.24	-0.03	-0.1	-0.08	-0.05	-0.21	-0.2
Cash And Short Term Investments	0.99	-0.01	0.05	0.93	-0.42	-1.0	-0.41	0.13	1.0	-0.49	-0.15		0.29	0.19	0.85	0.53	0.05	-0.45	1.0	0.34	-0.21	0.47	-0.14	-0.18	0.44	0.51
Common Stock Total Equity	0.31	0.33	0.32	0.19	0.21	-0.27	-0.31	0.34	0.29	0.08	0.17	0.29		0.45	0.27	0.33	0.34	0.3	0.29	0.78	0.02	0.47	-0.04	0.09	0.0	0.13
Common Stock Shares Outstanding	0.17	0.75	0.91	-0.14	-0.14	-0.15	-0.91	0.94	0.19	-0.33	-0.2	0.19	0.45		0.35	0.88	0.91	0.24	0.2	-0.01	-0.15	0.79	-0.15	-0.08	0.53	0.07
Other Current Assets	0.82	0.04	0.18	0.73	-0.6	-0.85	-0.54	0.33	0.85	-0.64	-0.23	0.85	0.27	0.35		0.63	0.16	-0.53	0.85	0.37	-0.15	0.46	-0.07	-0.14	0.58	0.55
Other Stockholder Equity	0.5	0.57	0.76	0.23	-0.35	-0.5	-0.99	0.82	0.53	-0.52	-0.24	0.53	0.33	0.88	0.63		0.76	-0.06	0.54	-0.04	-0.38	0.82	-0.35	-0.32	0.79	0.28
Total Liab	0.03	0.93	1.0	-0.3	0.01	0.0	-0.82	0.87	0.05	-0.17	-0.26	0.05	0.34	0.91	0.16	0.76		0.39	0.05	-0.09	-0.26	0.68	-0.27	-0.19	0.51	0.04
Property Plant And Equipment Gross	-0.39	0.44	0.36	-0.5	0.9	0.48	-0.01	0.23	-0.45	0.77	0.21	-0.45	0.3	0.24	-0.53	-0.06	0.39		-0.46	0.12	-0.34	0.05	-0.42	-0.28	-0.24	-0.41
Total Current Assets	0.99	-0.01	0.06	0.93	-0.42	-1.0	-0.42	0.14	1.0	-0.5	-0.15	1.0	0.29	0.2	0.85	0.54	0.05	-0.46		0.33	-0.21	0.47	-0.15	-0.18	0.44	0.52
Common Stock	0.38	-0.02	-0.11	0.39	0.2	-0.34	0.11	-0.12	0.34	0.17	0.24	0.34	0.78	-0.01	0.37	-0.04	-0.09	0.12	0.33		0.06	0.14	0.04	0.08	-0.19	0.12
Non Current Liabilities Total	-0.26	-0.21	-0.25	-0.17	-0.34	0.2	0.37	-0.19	-0.21	-0.31	-0.03	-0.21	0.02	-0.15	-0.15	-0.38	-0.26	-0.34	-0.21	0.06		-0.11	0.99	0.99	-0.54	-0.18
Current Deferred Revenue	0.44	0.56	0.67	0.2	-0.19	-0.44	-0.81	0.62	0.47	-0.47	-0.1	0.47	0.47	0.79	0.46	0.82	0.68	0.05	0.47	0.14	-0.11		-0.11	-0.02	0.52	-0.08
Short Term Debt	-0.2	-0.21	-0.25	-0.11	-0.42	0.13	0.35	-0.21	-0.14	-0.38	-0.08	-0.14	-0.04	-0.15	-0.07	-0.35	-0.27	-0.42	-0.15	0.04	0.99	-0.11		0.98	-0.5	-0.15
Short Long Term Debt Total	-0.23	-0.14	-0.17	-0.17	-0.31	0.17	0.3	-0.14	-0.18	-0.31	-0.05	-0.18	0.09	-0.08	-0.14	-0.32	-0.19	-0.28	-0.18	0.08	0.99	-0.02	0.98		-0.52	-0.2
Other Liab	0.41	0.35	0.52	0.24	-0.38	-0.43	-0.8	0.56	0.44	-0.49	-0.21	0.44	0.0	0.53	0.58	0.79	0.51	-0.24	0.44	-0.19	-0.54	0.52	-0.5	-0.52		0.4
Other Assets	0.51	-0.03	0.06	0.47	-0.43	-0.52	-0.22	0.23	0.51	-0.3	-0.2	0.51	0.13	0.07	0.55	0.28	0.04	-0.41	0.52	0.12	-0.18	-0.08	-0.15	-0.2	0.4

Click cells to compare fundamentals

Cellectar Biosciences Account Relationship Matchups

Cellectar Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.3M	58.7M	37.2M	21.6M	12.1M	16.0M
Other Current Liab	(127.0)	2.0M	2.3M	2.9M	7.3M	7.6M
Total Current Liabilities	2.8M	3.6M	4.0M	5.5M	12.9M	13.6M
Total Stockholder Equity	9.1M	54.8M	33.0M	15.5M	(1.4M)	(1.3M)
Property Plant And Equipment Net	783.9K	638.3K	549.1K	979.0K	1.6M	1.1M
Net Debt	(10.1M)	(56.7M)	(35.4M)	(19.3M)	(9.0M)	(9.5M)
Retained Earnings	(111.7M)	(126.8M)	(150.9M)	(179.5M)	(217.5M)	(206.6M)
Accounts Payable	1.3M	1.4M	1.4M	2.6M	5.6M	5.9M
Cash	10.6M	57.2M	35.7M	19.9M	9.6M	13.3M
Non Current Assets Total	865.1K	719.6K	630.3K	1.1M	1.6M	2.0M
Cash And Short Term Investments	10.6M	57.2M	35.7M	19.9M	9.6M	13.3M
Common Stock Total Equity	167.0	47.0	94.0	454.0	408.6	448.7
Common Stock Shares Outstanding	767.5K	2.0M	5.6M	7.1M	12.2M	12.8M
Liabilities And Stockholders Equity	12.3M	58.7M	37.2M	21.6M	12.1M	16.0M
Other Current Assets	771.0K	1.5M	1.7M	663.2K	888.2K	785.0K
Other Stockholder Equity	119.6M	161.5M	182.6M	193.6M	211.4M	222.0M
Total Liab	3.2M	3.9M	4.2M	6.1M	13.4M	14.1M
Property Plant And Equipment Gross	783.9K	356.0K	549.1K	979.0K	2.5M	2.6M
Total Current Assets	11.4M	57.9M	36.6M	20.5M	10.5M	14.0M
Accumulated Other Comprehensive Income	(5.8M)	(181.2K)	(309.4K)	(1.4M)	(1.6M)	(1.7M)
Common Stock	47.0	94.0	454.0	611.0	207.0	196.65
Non Current Liabilities Total	421.6K	301.7K	166.3K	553.0K	494.0K	469.3K
Current Deferred Revenue	965.1K	1.4M	2.0M	2.4M	2.8M	2.9M
Short Term Debt	105.9K	119.9K	270.9K	101.7K	59.0K	56.0K
Short Long Term Debt Total	527.5K	421.6K	301.7K	603.8K	553.0K	487.8K
Property Plant Equipment	435.1K	356.0K	549.1K	979.0K	881.1K	1.2M
Retained Earnings Total Equity	(84.3M)	(97.6M)	(111.7M)	(126.8M)	(114.1M)	(108.4M)
Preferred Stock Total Equity	995.8K	2.5M	1.1M	20.0M	23.0M	24.2M
Net Tangible Assets	7.9M	34.8M	31.7M	14.1M	16.2M	13.6M
Capital Surpluse	94.1M	108.3M	119.6M	161.5M	185.8M	103.4M
Capital Lease Obligations	527.5K	421.6K	301.7K	603.8K	553.0K	580.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:

How To Invest In Cellectar

Details

Is Cellectar Stock a good investment?

Details

What is Cellectar Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.41)

Return On Assets

(1.66)

Return On Equity

(7.97)

The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cellectar Cash vs Current Deferred Revenue Analysis

Cash vs Current Deferred Revenue

Cash vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Cash

Current Deferred Revenue

Cellectar Biosciences fundamental ratios Correlations

Cellectar Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cellectar Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.99	Retained Earnings
Net Debt	- 0.99	Total Assets
Net Debt	- 0.95	Total Stockholder Equity